Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

59.59 -0.51 (-0.85%)

Streaming Delayed Price Updated: 1:55 PM EST, Feb 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions ↗

August 07, 2024

Roche considers divesting Flatiron Health, acquired for $1.9 billion in 2018, highlighting the challenges big pharma faces with start-up investments. Flatiron's data aids Roche's oncology R&D despite...

Via Benzinga

Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus ↗

August 05, 2024

Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy...

Via Benzinga

Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now. ↗

August 02, 2024

Via The Motley Fool

Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It? ↗

July 29, 2024

Roche's latest breakthrough could be a game changer, but it's still too early to say.

Via The Motley Fool

Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On ↗

July 24, 2024

Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management.

Via Benzinga

Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch? ↗

July 23, 2024

Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.

Via The Motley Fool

Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier ↗

July 22, 2024

Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in...

Via Benzinga

This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It? ↗

July 22, 2024

This company hasn't made its debut on the weight-loss market yet, but it may.

Via The Motley Fool

Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche ↗

July 22, 2024

Neither is a leader right now, but one of them might be on track to change that.

Via The Motley Fool

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review ↗

July 19, 2024

The Nasdaq tumbled amid chip woes.

Via Investor's Business Daily

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗

July 18, 2024

Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.

Via Benzinga

VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday? ↗

July 18, 2024

It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels...

Via Benzinga

Topics Stocks

Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped ↗

July 17, 2024

Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock.

Via The Motley Fool

Pfizer And Roche Advance On Their Weight Loss Drug Journeys ↗

July 17, 2024

After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On...

Via Benzinga

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? ↗

July 17, 2024

Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest...

Via Benzinga

Roche Highlights Encouraging Data From Newly-Acquired Second Weight Loss Drug Candidate In Early-Stage Study ↗

July 17, 2024

Roche reported promising topline results from a Phase 1 trial of CT-996, an oral GLP-1 receptor agonist for type 2 diabetes and obesity. Participants experienced a mean weight loss of 6.1% in four...

Via Benzinga

3 Small-Cap Stocks With Explosive 2X Growth Potential ↗

July 08, 2024

Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.

Via InvestorPlace

Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients ↗

July 05, 2024

Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-free survival and overall survival in advanced non-squamous non-small cell lung...

Via Benzinga

AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway ↗

June 27, 2024

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.

Via Benzinga

Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case ↗

June 24, 2024

The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for...

Via Benzinga

Topics Lawsuit

Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗

June 21, 2024

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.

Via Benzinga

Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost ↗

June 21, 2024

How much Sarepta can hope to earn from Elevidys is unclear due to its cost, $3 million, and that it's not a cure. Yet SRPT stock is surging.

Via InvestorPlace

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy ↗

June 21, 2024

The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.

Via Benzinga

Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win ↗

June 11, 2024

An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.

Via Investor's Business Daily

Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside ↗

June 07, 2024

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

Via Benzinga

Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations ↗

June 06, 2024

Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis.

Via Benzinga

2 Cathie Wood Biotech Stocks That Could Be Worth the Risk ↗

May 29, 2024

You don't need to buy her picks, but it's worth understanding them.

Via The Motley Fool

If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today ↗

May 26, 2024

What would a $100 investment in Viking Therapeutics back in 2022 be worth today? Prepare to be surprised.

Via The Motley Fool

Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies ↗

May 23, 2024

U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq.

Via Benzinga

Topics Lawsuit

This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan ↗

May 21, 2024

The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.